POLISCOPE
Back to feed
NewsPBS NewsHourMay 5, 2026United States

White House Projects $529 Billion in Savings from New Drug Pricing Deals

Photo: PBS NewsHour

The White House estimates that new agreements with pharmaceutical companies to align U.S. drug prices with international rates could save $529 billion over the next decade. While the administration touts these deals as a major step in lowering costs, Democratic lawmakers and outside economists have raised questions regarding the transparency of the agreements and the actual impact on patient out-of-pocket expenses.

Prescription DrugsHealthcare PolicyEconomyMedicaidPharmaceutical IndustryBudget & Appropriations
Read the full story at PBS NewsHour

Why It Matters

The policy aims to lower prescription drug costs for U.S. consumers and save federal and state governments $64.3 billion in Medicaid spending over the next 10 years, though the specific terms of the deals remain undisclosed.

Key Facts

  • The White House estimates $529 billion in total savings over the next decade from new drug-pricing deals.
  • Federal and state governments are projected to save $64.3 billion on Medicaid over the next 10 years.
  • One internal model suggests potential savings could reach as high as $733 billion over a decade.
  • 17 leading pharmaceutical companies have entered into these pricing agreements.
  • The administration has not released the full text of the agreements, citing sensitive financial data and trade secrets.
  • Americans spent $467 billion on prescription drugs in 2024.
  • A report from Sen. Bernie Sanders' staff found that 15 of the participating companies saw combined profits jump 66% to $177 billion over the past year.
  • The Congressional Budget Office previously estimated a similar plan could reduce drug prices by more than 5%.
  • Senate Democrats have proposed a measure requiring the administration to disclose the terms of the agreements.

Who's Mentioned

PersonRon Wyden“Senate Finance Committee Ranking Member”PersonRobert F Kennedy Jr“Health Secretary”OrganizationCongressional Budget Office“Provided independent analysis of similar pricing plans”PersonBernie Sanders“U.S. Senator”OrganizationDepartment of Health and Human Services“Promoting the drug-pricing deals”PersonDonald Trump“President of the United States”OrganizationWhite House Council of Economic Advisers“Conducted the savings analysis”